Sanofi SA

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

23 апр 2024 01:00:00 Источник Nasdaq GlobeNewswire

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

17 апр 2024 01:00:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2024

12 апр 2024 14:05:27 Источник Nasdaq GlobeNewswire

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

08 апр 2024 12:00:00 Источник Nasdaq GlobeNewswire

Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

22 мар 2024 02:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - February 2024

15 мар 2024 15:04:03 Источник Nasdaq GlobeNewswire

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

11 мар 2024 02:00:00 Источник Nasdaq GlobeNewswire

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

24 фев 2024 09:51:53 Источник Nasdaq GlobeNewswire

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

23 фев 2024 12:45:30 Источник Nasdaq GlobeNewswire

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

23 фев 2024 01:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

22 фев 2024 13:02:45 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - January 2024

20 фев 2024 17:40:58 Источник Nasdaq GlobeNewswire

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

16 фев 2024 01:00:00 Источник Nasdaq GlobeNewswire

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

15 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

05 фев 2024 02:00:00 Источник Nasdaq GlobeNewswire

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

01 фев 2024 01:30:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

01 фев 2024 01:30:00 Источник Nasdaq GlobeNewswire

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

25 янв 2024 14:30:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

23 янв 2024 01:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - December 2023

17 янв 2024 16:57:07 Источник Nasdaq GlobeNewswire